Skip to main content
TR

Triumvira Immunologics

Austin, United States
Last funding
$45.0M
Series AMar 2022

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

Backed byB CapitalNorthpond VenturesOceanpine CapitalLeaps by BayerViva Biotech

About Triumvira Immunologics

How much funding has Triumvira Immunologics raised?

Triumvira Immunologics has raised $45.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.

Who are Triumvira Immunologics's investors?

Triumvira Immunologics's investors include B Capital, Northpond Ventures, Oceanpine Capital, Leaps by Bayer, Viva Biotech.

Where is Triumvira Immunologics headquartered?

Triumvira Immunologics is headquartered in Austin, United States.

What does Triumvira Immunologics do?

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

What stage is Triumvira Immunologics at?

Triumvira Immunologics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Triumvira Immunologics — Funding & Investors." VCBacked, March 17, 2022, https://www.vcbacked.co/company/triumvira-immunologics. Accessed November 17, 2026.
APA
VCBacked. (2022). Triumvira Immunologics — Funding & Investors. Retrieved November 17, 2026, from https://www.vcbacked.co/company/triumvira-immunologics
Wikipedia (cite web)
{{cite web |title=Triumvira Immunologics — Funding & Investors |url=https://www.vcbacked.co/company/triumvira-immunologics |website=VCBacked |access-date=November 17, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Triumvira Immunologics? Request a listing update

Founder contacts
m***@triumvira.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →